What They Do: BioTech is poised to be a part of the $126 Billion Pain Management industry. The Company's goal is to have 100 or more BioTech Laser(TM) Centers operating nationwide, similar to the 80 Lasik-Plus Eye Vision Centers operating. BioTech has finalized a strategic franchise alliance that will put BioTech on the fast-track.
BioTech Medics (BMCS) has developed proprietary pain management protocols utilizing patented FDA 510(k) cleared high powered deep penetrating medical therapeutic lasers for reducing or eliminating muscular, skeletal, nerve and/or arthritic pain over the entire body. The procedures are drug-free, quick (15 to 30 minutes) safe and non-invasive. BioTech has affiliated centers operating in Dallas, Kansas City (Overland Park), Albuquerque and Santa Fe, NM. A new center is pending in Newport Beach.
BioTech's advantage over competition is their proprietary protocols for the high-powered therapeutic medical lasers that the patient feels healing their body. Most competitors use "cold lasers" that operate with 5,000 to 12,000 times less power. Patients cannot feel a cold laser. Back pain, carpal tunnel, shoulder, knees and hip pain are treated in each center.
Generex Biotechnology Corporation (Nasdaq: GNBT) Closed at $0.53, and Pevion Biotech Ltd.announced today they have signed an agreement to work together to develop next-generation vaccines and immunotherapeutic products. The initial goal of the collaboration will be to investigate synergies in the cancer vaccine approaches of the two companies. Both companies have in-depth experience in developing immunotherapeutic vaccines for cancers.
What They Do: Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device.
Nymox Pharmaceutical Corporation (Nasdaq NYMX) Closed at $3.06. Today announced new results from a recently completed multi-center U.S. clinical study of NX-1207, the Company's innovative investigational drug for benign prostatic hyperplasia (BPH). The evidence indicates that NX-1207 can markedly reduce the incidence of nocturia, a particularly bothersome symptom of nighttime urination associated with BPH. After 90 days, subjects treated with a therapeutic dose of NX-1207 had a mean 49% reduction in nocturia symptoms, which was statistically significant compared to baseline (p less than .001).
What They Do: Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs and diagnostic devices. Its products under development include NX-1207, a treatment for benign prostatic hyperplasia.
Valence Technology (Nasdaq: VLNC) Closed at $2.25. Today announced that it has entered into a multi-year non-exclusive supply agreement with PVI for Valence’s U-Charge® XP Energy Storage Systems. PVI develops and manufactures commercial electric vehicles including electric buses under the GEPEBUS brand and trucks in partnership with Renault Trucks.
What They Do: Valence Technology is an international leader in the development of lithium phosphate energy storage solutions. The company has redefined lithium battery technology and performance by marketing the industry’s first safe, reliable and rechargeable lithium phosphate battery.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com has been a leading site for news on small-cap stocks since 1999. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select small-cap stocks, to register visit http://www.smallcapreview.com/subscribe.htm. SmallCapReview.com has been compensated three thousand five hundred dollars by a third party Green Horseshoe for its efforts in profiling BioTech Medics.
